117652-28-5

Basic information

• Product Name: 4-hydroxy-3-methoxymethamphetamine
• Synonyms: 4-Hydroxy-3-methoxymethamphetamine; 2-Methoxy-4-(2-(methylamino)propyl)phenol; 4,3-Hmm; Phenol, 2-methoxy-4-(2-(methylamino)propyl)-
• CAS NO: 117652-28-5
• Molecular Formula: C₁₁H₁₇NO₂
• Molecular Weight: 195.26
• Mol File: 117652-28-5.mol

Chemical Properties

• Boiling Point: 311.5°Cat760mmHg
• Flash Point: 142.2°C
• Appearance: /
• Density: 1.044g/cm³
• Vapor Pressure: 0.000306mmHg at 25°C
• Refractive Index: 1.523
• CAS DataBase Reference: 4-hydroxy-3-methoxymethamphetamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxy-3-methoxymethamphetamine(117652-28-5)
• EPA Substance Registry System: 4-hydroxy-3-methoxymethamphetamine(117652-28-5)

Safety Data

• Hazardous Substances Data: 117652-28-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
HMMA is used as a research compound for understanding the metabolic pathways and pharmacological effects of MDMA. It aids in the investigation of the neurotoxicity and long-term effects associated with MDMA use, which is crucial for developing potential treatments and interventions for MDMA-related health issues.
Used in Toxicological Analysis:
HMMA is utilized as a biomarker in toxicological analysis to detect the presence of MDMA in biological samples. This helps in forensic investigations and understanding the extent of MDMA use and its potential health risks.
Used in Drug Metabolism Studies:
HMMA serves as a key metabolite in drug metabolism studies, providing insights into how MDMA is processed and eliminated from the body. This information is valuable for developing safer and more effective drug therapies and for understanding the mechanisms of drug-induced toxicity.
Used in Neuropharmacology:
HMMA is employed in neuropharmacological research to explore its effects on the central nervous system. This helps in understanding the mechanisms of action of MDMA and its potential implications for neurological health and cognitive function.

InChI:InChI=1/C11H17NO2/c1-8(12-2)6-9-4-5-10(13)11(7-9)14-3/h4-5,7-8,12-13H,6H2,1-3H3

Upstream product

• 2503-46-0 1-(4-hydroxy-3-methoxyphenyl)2-propanone 
• 593-51-1 methylamine hydrochloride 
• 97-53-0 4-allylguaiacol 
• 408325-58-6 4-(2-bromo-propyl)-2-methoxy-phenol 
• 74-89-5 methylamine 

Downstream Products

• 853062-39-2 C₁₆H₂₅NO₄ 

Relevant articles and documents

Gas chromatographic/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry

A qualitative GC/MS profile was obtained and its mass spectrometric features characterized for the analysis of the enantiomers of (RS)-3,4-methylenedioxmethamphetamine (MDMA) and its metabolites (RS)-3,4- methylenedioxyamphetamine (MDA), (RS)-4-hydroxy-3-methoxymethamphetamine (HMMA) and (RS)-4- hydroxy-3-methoxyamphetamine (HMA). A chiral derivatization method was selected to obtain the diastereomers required for the separation of the respective enantiomers with a non-chiral GC stationary phase. The selected derivatization consisted of a reaction with N-heptafluorobutyryl-(S)-prolyl chloride combined with a consecutive reaction with N-methyl-N-trimethylsilyltrifluoracetamid, resulting in N-[heptafluorobutyryl-(S)-prolyl]-O-trimethylsilyl derivatives. Detection was carried out with electron ionization and positive chemical ionization (PCI) ion trap mass spectrometry. Mass spectra of the derivatives of reference standards of the compounds of interest obtained with PCI demonstrated that this method simultaneously induces proton and charge-transfer reactions in the ion trap. The advantage is that high mass information is provided while some fragmentation remains to elucidate structural details. Subsequently, in three urine samples obtained from different and unrelated MDMA intoxications the enantiomers of MDMA and MDA were identified. In some urine samples also HMMA and/or HMA were found. In addition to these compounds, an unexpected compound and/or additional chiral metabolite, N-hydroxy-(RS)-3,4-methylenedioxyamphetamine, was identified in two out of three urine samples. Preliminary results also indicated an enantioselective metabolism in the N-demethylation pathway for MDMA in humans.

ASSAY FOR ENTACTOGENS

Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxyamphetamine (MDA)3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylenedioxy-ethylamphetamine (MDEA) and 4-hydroxy-3-methoxy-methamphetamine (HMMA). The method comprises providing in combination in a medium (i) a sample suspected of containing the compound and (ii) an antibody raised against a compound of Formula I that comprises a protein. The medium is examined for the presence a complex comprising the compound and the antibody where the presence of such as complex indicates the presence of the compound in the sample. In one aspect of the above embodiment, the combination further comprises a label conjugate of the compound Formula I.